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1. Introduction 
Diabetes mellitus is a major public health problem and its’ prevalance is contuniously rising 
especially in developed or developing countries. According to World Health Organization 
(WHO) data the prevalence of diabetes for all age-groups worldwide was estimated to be 
2.8% in 2000 and 4.4% in 2030. The total number of people with diabetes is projected to rise 
from 171 million in 2000 to 366 million in 2030 (1).  Despite of improved treatment options 
for both diabetes mellitus and other associated risk factors, diabetic nephropathy is still a 
major problem causing increased morbidity and mortality as the increase in total number of 
diabetic patients finds a reflection in increased prevalence of diabetic patients in end stage 
renal disease (ESRD) population. There are some studies reporting decreased incidence of 
diabetic nephropaty in developed countries as a result of better glycemic control and 
agressive treatment of hypertension with new generation antihypertensives (2). However  
total number of diabetic nephropathy patients seems to be increasing as a result of increased 
numbers of diabetic patients and diabetes has become the primary cause of ESRD in the 
developed countries. Approximately 44% of new patients entering dialysis in the United 
States are diabetics. In the United States, approximately 20.8 million people, or 7.0% of the 
population, are estimated to have diabetes, with a growing incidence. Roughly one third of 
this population, 6.2 million, is estimated to be undiagnosed with type 2 diabetes (3, 4). 
Similar to these findings prevalence of diabetic nephropahty also increases in in developing 
countries For example, according to Turkish Society of Nephrology data prevalence of 
diabetic ESRD patients increased form 7% to 32.5% from 1991 to 2008. A similar trend was 
also observed for hypertensive nephropathy which raised from 6.3% to 26.8% (5). This 
hypertensive population is important as according to some previous reports, only one third 
of essential hypertension patients has normal blood glucose metabolism at diagnosis (6). So 
it is possible that prevalence of pure diabetic or pure hypertensive nephropathy is lower 
than predicted but the combination of these two pathological condition is very high in 
otherwise healthy and ESRD populations.  
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2. Risk factors 
Multiple risk factors for development of diabetic nephropathy were defined. Most 
important of these seems to be the duration of diabetes mellitus. 20-30% of type I diabetics 
are supposed to have clinically significant renal involvement (microalbuminuria) after 20 
years duration and 15-20% develop ESRD after an additional 10 year (7, 8). These durations 
are not well defined for type 2 diabetics. 5-25% of these patients might have clinically 
significant renal failure or even ESRD (1%) at time of diagnosis and approximately 20-30% 
reach ESRD at 20 years duration (9). The impact of age at time of diabetes diagnosis on 
development of renal failure is not clear. Among patients with type 2 diabetes, increasing 
age, along with increasing duration of diabetes was reported to be associated with increased 
risk for developing albuminuria (10). However some contradicting studies report that, 
patients who developed diabetes prior to age 20 had a higher risk of progressing to end-
stage renal disease (25 versus 5 per 1000 patient years at risk) (11). For type 1 diabetes, the 
risk of developing ESRD was reported to be very low for patients diagnosed prior to age 5; 
however at older ages, the relationship of age to progression to ESRD is uncertain (12, 13). 
Poor glycemic control is another important risk factor for development of diabetic renal 
involvement. The Diabetes Control and Complications Trial (DCCT) demonstrated that 
interventions that improve glycemic control in patients with type 1 diabetes mellitus reduce 
the risk of development and slow the progression of diabetic microvascular disease, and 
may also protect against the occurrence of macrovascular disease (14).  The United Kingdom 
Prospective Diabetes Study (UKPDS), a study of over 4000 patients with prolonged follow-
up, suggests that strict control also results in a reduced risk of microvascular disease in 
patients with type 2 diabetes (15). 
Hypertension, another important risk factor, is very common in diabetic patients. In fact 
hypertension is a cause and also a result of diabetic renal disease. Among those with type 1 
diabetes, the incidence of hypertension rises from 5% at 10 years, to 33% at 20 years, and 
70% at 40 years (16). The blood pressure typically begins to rise within the normal range 
about three years after the onset of microalbuminuria. Ultimately, the incidence of 
hypertension is approximately 15 to 25% in all patients with microalbuminuria and 75 to 
85% in those with overt diabetic nephropathy (17). On the other hand type 2 diabetic 
patients have different characteristics. Most of them already have hypertension, even 
without renal involvement/microalbuminuria at the time of diagnosis (18). Also essential 
hypertension patients have some glucose metabolism abnormalities including insukin 
resistance without overt diabetes at time of diagnosis (6).  
Obesity and hyperlipidemia might also cause progression of diabetic nephropathy while 
weight loss and control of hyperlipidemia by using statins might improve renal status (19-
22).  
Approximately one-half of patients with type 1 diabetes of less than five years duration 
have an elevated glomerular filtration rate (GFR) that is 25 to 50 percent above normal and 
this situation was reported to have negative effects on disease progression (23). If GFR is 
above 150 mL/min risk for developing microalbuminuria significantly increases. In one 
prospective study, for example, patients with type 1 diabetes and a GFR above 125 mL/min 
had a risk of developing microalbuminuria within 8 years of approximately 50 percent 
versus only 5 percent in patients with a lower GFR that was similar to that seen in 
nondiabetics (23).  
www.intechopen.com
 
Diabetic Nephropathy; Clinical Characteristics and Treatment Approaches 
 
265 
Some genetic susceptibilities for developing diabetic renal disease were also reported. Most 
important of these factors are race, family tendencies and ACE gene polymorphisms (24-28). 
Considering gene polymorphisms; in patients with type 2 diabetes, the ACE/DD 
polymorphism was reported to associate with an increased risk for the development of 
diabetic nephropathy, more severe proteinuria, greater likelihood of progressive renal 
failure, and mortality on dialysis (26-28). 
3. Pathophysiology 
Development of diabetic nephropathy depends on different pathogenic processess. Major of 
these pathyways will be summarized below 
a. Glomerular hyperfiltration: Studies in experimental animals indicate that dilatation of 
the afferent (precapillary) glomerular arteriole plays an important role in the 
hyperfiltration response, by raising both the intraglomerular pressure and renal blood 
flow (29). Some hormonal factors including insulin-like growth factor I (IGF-1), atrial 
natriuretic factor and sex hormones were speculated to have effects on hyperfiltration. 
Most important of these seems to be IGF-1 which induces hyperfiltration, renal 
vasodilatation and hypertropy in experimental models (30). Increased intracellular 
sorbitol accumulation, hyperglycemia, glycosylation endproducts and increased 
sodium reabsorption and tubuloglomerular feedback also has effects on glomerular 
hyperfiltration 
b. Hyperglycemia and AGEs: Hyperglycemia is known to have a direct effect on 
mesangial expansion and injury, a result possibly secondary to increased matrix 
production or glycosylation of matrix proteins. Glycosylation of tissue proteins also 
may contribute to the development of diabetic nephropathy. Chronic hyperglycemia 
causes nonenzymatic glycosylation of free amino acids on circulating or tissue proteins 
and this process forms reversible early glycosylation products and later irreversible 
advanced glycosylation end products (AGEs). Circulating AGE levels are increased in 
particularly diabetics with renal insufficiency, because AGEs are normally excreted in 
the urine. The net effect is tissue accumulation of AGEs, in part by crosslinking with 
collagen, which can contribute to the associated renal and microvascular complications 
(31, 32). 
c. Prorenin: A recent experimental model has reported a possible pathogenic role for 
prorenin in the development of diabetic nephropathy in which prolonged prorenin 
receptor blockade prevented the development of nephropathy without alterin 
angiotensin II activity (33). 
d. Proinflammatory cytokines and growth factors: A group of proinflammatory, 
profibrotic cytokines and growth factors were speculated to have effects on diabetic 
nephropathy pathogenesis. Most important of these are vascular endothelial growth 
factor (VEGF), transforming growth factor – beta (TGF-ß). Experimental models 
reported that VEGF blockade improves albuminuria in diabetic nephropathy (34). 
Similarly the combination of an anti-TGF-beta antibody and an ACE inhibitor 
completely normalized proteinuria in experimental diabetic nephropathy models (35). 
e. Proteinuria: Final result of above mentioned pathogenic factors is proteinuria. Normal 
protein discharge in urine is lower than 30 mg/day for albumin and 150 mg/day for 
total protein. Microalbuminuria (30-300 mg/day) is a critical treshold for diabetic 
nephropathy and after this stage untreated patients usually develop overt proteinuria 
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(> 300 mg/day microalbuminuria). Proteinuria was reported to induce inflammation, 
fibrosis, and it is also have direct tubular toxicity which all promote development of 
diabetic nephropathy 
4. Histopathological changes 
All components of renal infrastructure can be affected by diabetic nephropathy. Some of these 
changes are specific for diabetes, some not. Most common and important changes are capillary 
basal membrane thickening, diffuse glomerulosclerosis and nodular glomerulosclerosis 
(Kimmelstiel – Wilson nodules). Nodular glomerulosclerosis was described by Kimmelstiel 
and Wilson in 1936. These nodules are eosinophilic and PAS positive hard masses which are 
located in the central regions of peripheral glomerular lobules. They appear to be of mesengial 
origin and when they are pathogomonic for diabetic nephropathy however they are not 
universal and found only in 10-40% of patients. The diffuse mesengial lesions are more 
frequent than nodular glomerulosclerosis and present in 50-90% of patients. They include 
increased mesengial matrix, basala membrane thickening, capillary narrowing, hyalinization 
and periglomerular fibrosis. Afferent and efferent arteriolar hyalnization is highly specific for 
diabetic nephropathy, on the other hand only afferent arteriol involvement is a finding of 
hypertensive nephrosclerosis.  
5. Clinical manifestations and natural history 
Clinical stages of type 1 diabetes mellitus renal involvement is summarized in Table-1. 
These stages are also accepted for type 2 diabetic patients however they might not always 
follow these steps (36). ESRD is not the only major consequence of diabetic nephropathy but 
patients have increased risk of cardiovascular disease , morbidity and mortality even in the 
early stages of nephropathy. Microalbuminuria (30-300 mg/day albuminuria) is the first 
clinical sign of diabetic nephropathy and this situation is highly associated with other 
complications of diabetes like cardiovascular disease and retinopathy. 24 hour urine or spot 
urine albumin / creatinine ratios should be used for microalbuminuria follow-up. Overt 
proteinuria is defined as >300 mg/day albuminuria and at this stage total protei,n loss in 
urine might exceed 1g/day. 5-7 years after development of overt proteinuria these patients 
usually develop ESRD. 
6. Diagnosis and differential diagnosis 
Proteinuria developing in a diabetic patient is an important marker for diabetic 
nephropathy however in case of atypical presentation renal biopsy might be indicated. A 
typical diabetic nephropathy presentation is a type 1 diabetes history for at least 10 years, 
presence of retinopathy, previous microalbuminuria, no macroscopic hematuria and 
microscopically inactive urinary sediment. Type 2 diabetic patients might not have this kind 
of a clinic and as previously mentioned 5-25% of these patients might have clinically 
significant renal failure or even ESRD (1%) at time of diabetes diagnosis (9). In case of 
atypical presentation a renal biopsy is usually indicated. Possible atypical presentations are 
as follows; short diabetes duration (> 10 yrs for type 1 diabetics), no previous retinopathy, 
overt proteinuria without previous microalbuminuria, macroscoic hematuria, red cell or 
leucocyte casts, presence of systemic manifestations of any other disease that also can 
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involve kidneys like collagen tissue disorders, amyloidosis etc, rapid decline in renal 
function without significant proteinuria. Long diabetes duration, previous retinopathy and 
microalbuminuria might not always be present in type 2 diabetics so in these patients 
presence of glomerulonephritis clinical features or any other systemic disease with possible 
renal involvement are biopsy indications.  
 
 
Stage 
Duration of 
diabetes 
mellitus 
GFR and 
renal 
perfusion 
Urine 
findings 
Serum 
findings 
Clinical 
findings 
Morpho-
logical 
findings 
1. Nephro-
megaly and 
hyper-
filtration 
stage 
At diagnosis Increased 
Reversible 
albuminuria
No 
significant 
finding 
Increased 
renal size 
Glomerular 
hypertrophy 
2. Latent 
stage 
2-5 years 
Normal/Incr
eased 
No 
significant 
finding 
No 
significant 
finding 
No significant 
finding 
Increased 
basal 
membrane 
thickness 
3. Incident 
diabetic 
nephropathy 
stage 
5-15 years 
Normal/Incr
eased 
Microalbumi
nuria (30-300 
mg/day) 
No 
significant 
finding 
Hypertension 
Increased 
basal 
membrane 
thickness and 
mesengial 
expansion 
4. Overt 
diabetic 
nephropathy 
stage 
10-25 years
Decreasing 
progressively
Overt 
proteinuria
Increased 
creatinine 
Hypertension 
and 
significant 
nephropathy 
Diffuse/nod
ular 
glomeruloscl
erosis 
5. End stage 
renal disease 
stage 
15-30 years Decreased 
Overt 
proteinuria
Uremia 
Hypertension 
and 
significant 
nephropathy 
Glomeruloscl
erosis 
Table 1. 
Diabetic patients are also prone to some renal diseases or complications which might need 
to be differentialy diagnosed. Almost every form of glomerular diseases were reported in 
diabetic nephropathy patients however membranous nephropathy is the most common one. 
Papillary necrosis, renovascular diseases (arterial or venous), bladder autonomic 
neuropathy, acute or chronic pyelonephritis, radiocontrast nephropathy and renal 
tuberculosis should always be kept in mind while evaluating a diabetic patient with renal 
findings.  
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7. Treatment and prevention of diabetic nephropathy 
Strict glycemic control decreases development of diabetic nephropathy in both type 1 and 2 
diabetics. Intensive insulin therapy partially reverse the glomerular hypertrophy and 
hyperfiltration, delay the development of microalbuminuria, reduce the onset or 
progression of diabetic nephropathy compared to less intensive therapy, stabilize or 
decrease protein excretion in patients with microalbuminuria (14, 15, 37, 38). Intensive 
glycemic not only slow or even prevent development of diabetic nephropathy but also 
decrease morbidit and mortality ferom other diabetic complications. However the less 
prominent benefit from strict glycemic control in overt diabetic nephropathy indicates that 
factors other than hyperglycemia contributes to the glomerular injury. Reducing the 
intraglomerular pressure with dietary protein restriction or antihypertensive therapy with 
an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) 
can minimize progression of or even prevent glomerular disease in the absence of glycemic 
control. There is now clear evidence that antihypertensive therapy (particularly with RAS 
blockers) and perhaps protein restriction can reduce the rate of progression in patients with 
type 1 diabetes and overt nephropathy. 
Hypertension increases rate of diabetic nephropathy progression. DCCT and UKPDS 
trialsdemonstrated that strict blood pressure control decreases microalbuminburia and 
macroalbuminuria development by 29% and 39% respectively in 6 years follow-up period 
(14, 15). WHO and JNC advises to keep blood pressure below 130/80 mmHg in diabetic 
patients. In JNC-VII quideline even a lower level (125/75 mmHg) was proposed for 
prevention and/or slowing diabetic nephropathy progression (39). ACEI preference in 
diabetic patients is also recommended in these quidelines. ACEI not only decrease 
intraglomerular pressure (so decrease proteinuria) by their hemodynamic effects but also 
decrease glomeruler size and fibrotik process. ACEI were also reported to increase negative 
charge of basal  membrane and so decrease proteinuria. ARBs could also be used alone or in 
combination with ACEI for increasing nephroprotection (40, 41). Nondihydropyridine class 
calcium antagonists (NDHCB) are also recommended as a combination with RAS blockers. 
In BENEDICT trial it was demonstrated that ACEI-NDHCB combination might delay 
development of microalbuminuria in hypertensive diabetic patients without proteinuria 
(42). Salt intake should be restricted (< 70 mEq/day) for a beter antirpoteinuric effect as salt 
seems to blunt effects of both RAS blockers and NDHCB (43, 44). Aldosterone antagonists 
were also reported to reduce proteinuria when used alone, and to have an additive effect on 
proteinuria when used in combination with an ACE inhibitor or an ARB in both type 1 and 
type 2 diabetes (36, 45). Further blood pressure reduction may partially explain the 
beneficial effect, although an anti-inflammatory mechanism has also been proposed (46). 
However hyperkalemia in combination treatment ACEI/ARB and aldosterone antagonists) 
is a significant problem especially in advanced diabetic nephropathy. 
Low protein diet decreases hyperfiltration in early stages of diabetic nephropathy and also 
could slow down GFR loss. However very low protein diets (< 0.6/g/kg/day) could cause 
malnutrition which is an important mortality risk factor in ESRD population so 0.8 
g/kg/day protein diets and essential amino acid supplementations are usually 
recommended (47). 
Hyperlipidemia should also be screened in diabetic patients and must be treated with 
statins or fibrats if needed. Diabetic patients without hypertension but under simvastatin 
treatment were reported to have a 25% decrease in microalbuminuria levels (48). 
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8. Renal replacement treatment in diabetic esrd patients 
Diabetic patients usually need renal replacement therapy (RRT) in earlier stages of renal 
failure. It was reported that nondiabetic patients start receiving RRT when GFR falls below 
10 ml/min but on the other hand diabetics need RRT with higher GFR (15-20 ml/min) levels 
(49). These patients are prone to hypervolemia and lung edema due to accompanying 
cardiac problems and malnutrition due to proteinuria and dietary restrictions. Diabetic 
patients developing diuretic resistant edema might need ultrafiltration and start RRT even 
with higher GFR values.  
Patient survival in diabetics on maintenance dialysis is lower than that seen in nondiabetics 
with end-stage renal failure due to chronic glomerular disease or hypertension (50). As 
noted in the 2005 USRDS database, only approximately 25 percent of patients with diabetes 
survived five years after initiation of dialysis and  cardiovascular disease is the most 
common cause of death, accounting for more than one-half of cases (50).  
Renal transplantation is a choice of RRT in diabetic ESRD patients however five year 
survival is clearly lower than other ESRD patients ranging from 75% to 83% (51). Despite of 
this poor outcome, transplantation still result in decreased  extrarenal vascular diseaseand 
better quality of life compared with either hemodialysis or peritoneal dialysis (51).  
Making choice of dialysis modality in diabetic patients is similar with nondiabetic patients. 
Comorbid conditions, home situation, independence and motivation of the patient,  ability 
to tolerate volume shifts, patients’ desire,  status of the vasculature and/or abdomen should 
be evaluated for each patient. The relative effect of hemodialysis and CAPD on survival in 
diabetic patients is uncertain. Initial reports suggested that CAPD was associated with a 
better outcome (52). However data from the USRDS case-mix study suggest that mortality 
may actually be increased in diabetic patients receiving CAPD (53). A subsequent very large 
study attempted to assess the impact of multiple risk factors, including diabetes, on survival 
after initiation of either hemodialysis or peritoneal dialysis. Utilizing data from 398,940 
patients who initiated dialysis between the years 1995 to 2000 (54). Mortality risk was 
significantly higher on hemodialysis than PD among younger diabetics with no 
comorbidity. By comparison, hemodialysis was associated with a lower mortality risk in 
older diabetics with either no comorbidity or a baseline comorbidity.  
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